ClinicalTrials.gg
CompletedNCT00645086Updated Mar 27, 2008

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

A Phase 3 interventional study of clarithromycin extended-release tablets and clarithromycin immediate-release tablets in Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)., sponsored by Abbott. Completed at 146 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2008-03-27.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
465
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.

Enrollment
21st of 82
465 · median 126
Started
2002
with 4 others
Phase 3
19 of 100
none open now
Registered
30th of 100
by date

Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 21st largest by enrollment of the 82 interventional ones that give a count, is one of 5 that started in 2002, is one of 19 in phase 3, and was the 30th registered.

Bronchitis, Chronic

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

Browse Bronchitis, Chronic studies →

Open to participants now

7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Bronchitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

To compare the efficacy of a 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) in the treatment of acute bacterial exacerbation of chronic bronchitis.

03

Conditions studied

  • Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory subject who does not require intravenous antibiotic therapy.
  • Subject who has a medical history of chronic bronchitis.
  • A history of regular medication use (>=3 consecutive months within the past 2 years) to treat pulmonary disease.
  • Subject must have evidence of pulmonary function test abnormalities.
  • The onset of signs and symptoms of the current exacerbation must occur within 14 days before Evaluation 1.

Exclusion criteria

Exclusion Criteria:

  • Medical history of , allergic or adverse reactions to clarithromycin, erythromycin, or any of the macrolide antibiotics.
  • A female who is pregnant or is lactating.
  • Subject who has suspected or known (positive chest radiograph) pneumonia.
  • Subject who has evidence of significant bronchiectasis (by CT) or atelectasis, active tuberculosis or other mycobacterial infection, bullous emphysema, pulmonary embolism, lung abscess, tumor (primary or ) involving the lung, pleural effusion, or cystic fibrosis that could confound the assessment of signs and symptoms of ABECB.
  • Subject who requires parenteral antibiotic therapy.
  • Subject who requires hospitalization for treatment of current episode of ABECB.
  • Subject who has any other infection or condition, which necessitates use of a concomitant systemic antibiotic.
  • Subject who has any underlying condition/disease, which would be likely to interfere with the completion of the course or absorption of study drug therapy or follow-up.
  • Subject who has a severe or complicated lower respiratory tract infection or a severely compromised respiratory status (i.e., oxygen dependent, requiring hospitalization).
  • Known significant renal or hepatic impairment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
465 participants (actual)

Study arms

  • Active comparator
    A

    Drug: clarithromycin extended-release tablets

  • Active comparator
    B

    Drug: clarithromycin immediate-release tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Response

    Time frame: 23 days

  2. Bacteriologic Response

    Time frame: 23 days

Secondary outcomes

  1. Adverse events assessment

    Time frame: 42 days with follow-up to a satisfactory conclusion

  2. Physical exam; Vital signs; Use of other medications and supplements

    Time frame: 42 days

  3. Laboratory evaluations

    Time frame: 23 days

07

Study locations

146 sites
  • Birmingham, Alabama 35235, United States
  • Birmingham, Alabama 35242, United States
  • Columbiana, Alabama 35051, United States
  • Hoover, Alabama 35216, United States
  • Mobile, Alabama 36608, United States
  • Montgomery, Alabama 36106, United States
  • Ozark, Alabama 36360, United States
  • Glendale, Arizona 85306, United States
  • Phoenix, Arizona 85006, United States
  • Sun City West, Arizona 85375, United States
  • Tucson, Arizona 85712, United States
  • Tucson, Arizona 85746, United States
  • Camden, Arkansas 71701, United States
  • Clovis, California 93611, United States
  • Corona, California 92879, United States
  • Fountain View, California 92708, United States
  • Fresno, California 93703, United States
  • Huntington Beach, California 92647, United States
  • Lakewood, California 90712, United States
  • Pasadena, California 91105, United States
  • Rancho Cucamonga, California 91730, United States
  • Roseville, California 95661, United States
  • San Diego, California 92103, United States
  • San Diego, California 92117, United States
  • San Diego, California 92123, United States
  • San Jose, California 95128, United States
  • Sylmar, California 91342, United States
  • Temecula, California 92591, United States
  • Torrance, California 90505, United States
  • Upland, California 91786, United States
  • Colorado Springs, Colorado 80909, United States
  • Loveland, Colorado 80538, United States
  • Wheat Ridge, Colorado 80033, United States
  • Waterbury, Connecticut 06708, United States
  • Brandon, Florida 33511, United States
  • Deland, Florida 32720, United States
  • Fort Lauderdale, Florida 33316, United States
  • Gainesville, Florida 32605, United States
  • Largo, Florida 33770, United States
  • Merritt Island, Florida 32953, United States
  • Miami, Florida 33157, United States
  • Miami, Florida 33186, United States
  • New Port Richey, Florida 34652, United States
  • Orlando, Florida 32806, United States
  • Panama City, Florida 32405, United States
  • Tallahassee, Florida 36078, United States
  • Tampa, Florida 33614, United States
  • Atlanta, Georgia 30342, United States
  • Blue Ridge, Georgia 30513, United States
  • Fort Gordon, Georgia 30905, United States
  • Marietta, Georgia 30060, United States
  • Rome, Georgia 30165-1698, United States
  • Coeur d'Alene, Idaho 83814, United States
  • Chicago, Illinois 60612, United States
  • Hines, Illinois 60141, United States
  • Orland Park, Illinois 60462, United States
  • Elkhart, Indiana 46514, United States
  • Evansville, Indiana 47712, United States
  • Indianapolis, Indiana 46254, United States
  • Wichita, Kansas 67207, United States
  • Lexington, Kentucky 40508, United States
  • Murray, Kentucky 42071, United States
  • Baton Rouge, Louisiana 70816, United States
  • Metairie, Louisiana 70006, United States
  • New Orleans, Louisiana 70128, United States
  • Sunset, Louisiana 70584, United States
  • Auburn, Maine 04210, United States
  • Chester, Maryland 21619, United States
  • Dewitt, Michigan 48820, United States
  • Livonia, Michigan 48152, United States
  • Saginaw, Michigan 48602, United States
  • St. Joseph, Michigan 49085, United States
  • Chesterfield, Missouri 63017, United States
  • Jefferson City, Missouri 65109, United States
  • Springfield, Missouri 65802, United States
  • St. Louis, Missouri 63110-1093, United States
  • Missoula, Montana 59804, United States
  • Omaha, Nebraska 68134, United States
  • Blackwood, New Jersey 08012, United States
  • Mount Laurel, New Jersey 08054, United States
  • Toms River, New Jersey 08755, United States
  • West Caldwell, New Jersey 07007, United States
  • Astoria, New York 11102, United States
  • Bronxville, New York 10708, United States
  • Buffalo, New York 14215, United States
  • Camillus, New York 13031, United States
  • New York, New York 10016, United States
  • Greensboro, North Carolina 27401, United States
  • Winston-Salem, North Carolina 27103, United States
  • Chardon, Ohio 44024, United States
  • Mogadore, Ohio 44260, United States
  • Toledo, Ohio 43614, United States
  • Toledo, Ohio 43617, United States
  • Zanesville, Ohio 43701, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Eugene, Oregon 97404, United States
  • Lake Oswego, Oregon 97035, United States
  • Medford, Oregon 97504, United States
  • Portland, Oregon 97219, United States
  • Bensalem, Pennsylvania 19020, United States

Showing the first 100 of 146 sites across 3 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002 and a primary completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2008
First posted
Mar 27, 2008
Start
Dec 2002
Primary completionActual
Apr 2004
Last update
Mar 27, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00645086
Lead sponsor
Abbott
First posted
Mar 27, 2008
Start date
Dec 2002
Primary completion
Apr 2004
Last update
Mar 27, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clarithromycin

Start the discussion